

08 August 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
---	--

Sub: Press release for the Un-audited Financial Results for the quarter ended on 30 June 2025.

Dear Sir/ Madam,

With reference to the above subject, we enclose herewith the Press release for the Un-audited Financial results for the quarter ended on 30 June 2025.

We request you to take note of the same and oblige.

Thank you.

For **Sai Life Sciences Limited**

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

Sai Life Sciences Limited Reports Revenue growth of 77% YoY

Q1FY26 Revenue at ₹496 Cr; EBITDA at ₹125 Cr; Net Profit at ₹60 Cr.

Hyderabad, August 08, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO) announced its financial results for the first quarter and Fiscal year 2026.

Financial Performance:

Particulars (₹ crores)	Q1FY26	Q1FY25	YoY%	FY25	FY24	YoY%
Revenue from Operations	496	280	77%	1695	1,465	16%
EBITDA	125	31	303%	425	300	42%
EBITDA Margin%	25%	11%	-	25%	20%	-
PBT	81	-18	447%	228	109	108%
PAT	60	-13	448%	170	83	105%
PAT Margin%	12%	-5%	-	10%	6%	-

Financial Highlights

- Revenue from Operations was ₹496 Cr for Q1FY26 compared to ₹280 Cr in Q1FY25, **an increase of 77%** driven primarily by strong growth in CDMO segment.
- EBITDA stood at ₹125 Cr. for Q1FY26 compared to ₹31 Cr in Q1FY25. **an increase of 305%**
- EBITDA margin **expanded by 14%** YoY to 25% in Q1FY26
- PAT for Q1FY26 stood at ₹60 crore
- Invested ₹134 crore in capital expenditure during Q1FY26

Business Highlights

- Commenced commercial operations at Bidar Unit IV (PB-11 Phase II), adding ~91 KL capacity and taking the total manufacturing capacity to ~700 KL.
- Inaugurated Peptide Research Center at Hyderabad R&D campus, strengthening capabilities in complex peptides and emerging modalities.
- Inaugurated 10,300 sq. ft. Biology facility with multiple laboratories, strengthening the company's discovery offering.
- Construction underway for new Medicinal Chemistry block with 200 fume hood capacity.
- Broke ground for a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early phase peptide development and Clinical Formulations.
- Commencing work on building an additional 200 KL production capacity at Unit IV, Bidar; to be ready by Q3FY27.
- Onboarded 253 scientists and technical staff to support scaling.

Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, "We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients' relationships that continue to anchor us through macroeconomic uncertainty and broader industry cycles.

As the nature of innovation in drug development evolves, we are proactively investing in the infrastructure and scientific depth required to support complex and emerging modalities. During the quarter, we inaugurated new Biology Labs that significantly strengthen our Integrated Discovery platform and enhance our ability to handle greater molecular complexity. We also broke ground on a new Process R&D Block at our Hyderabad campus, which will

nearly double our process R&D capacity and bring in next generation, data-rich process capabilities to handle increasingly complex molecules.

These are deliberate steps in our journey to be the partner of choice for advancing innovation in complex science. We remain committed to enabling our clients' aspirations with speed, scientific rigor, and an unrelenting focus on quality."

Mr. Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences Limited added," We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses.

Total revenue for the quarter stood at ₹496 Cr, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues, enabled by deeper engagement with global clients.

We recorded EBITDA of ₹125 Cr, growing 305% YoY, with margins expanding to 25%, an improvement of 14% YoY driven by operating leverage, scale efficiencies, and improved productivity across our sites.

During the quarter, we invested ₹134 Cr in capex. This includes investments in new R&D infrastructure and process development capabilities, enabling us to support complex and emerging modalities such as peptides, ADCs, and oligonucleotides.

As we look ahead, we remain optimistic about our growth trajectory. With a strong foundation in place, we are focused on scaling execution, strengthening client partnerships, and investing in technology and talent to deliver sustained performance and long-term value."

Earnings Call:

Sai Life Sciences will conduct earnings call at 4.00 PM (IST) on 8 August 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date	August 08, 2025
Time	04:00 PM – 5:00 PM (IST)
Dial-in Number	+91 22 6280 1107, +91 22 7115 8008
International Toll Free	USA: 18667462133 UK: 08081011573 Singapore: 8001012045 Hong Kong: 800964448
Pre-Registration Facility	Click here

About Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE)

Sai Life Sciences is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit www.sailife.com

For further details, please feel free to contact: Investorrelation@sailife.com

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.